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Growing evidence is now available on the use of S100B protein as a valuable marker of brain damage and its role as a neurotrophic
factor. Bearing in mind, among diﬀerent S100B protein properties that are still being investigated, the possibility of measuring this
protein in diﬀerent biological ﬂuids renders it suitable for use in several disciplines. This is the case with perinatal medicine where
even more noninvasive techniques are particularly desirable in order to ensure the minimal handling diagnostic and therapeutic
strategies. In this setting, the present minireview reports data on the presence and the usefulness of S100B protein as brain damage
marker and as a neurotrophic factor in the so-called unconventional biological ﬂuids such as saliva and human milk, respectively.
Results oﬀer new possibilities for the use of S100B in perinatal medicine as a key-protein for the investigations focusing on central
nervous system development and damage.
1.Introduction
The term S100B refers to a member of a multigenic family
of calcium-modulated proteins ﬁrst identiﬁed in 1965 by
Moore [1], each of which exhibits a unique pattern of tissue-
or cell type-speciﬁc expression; the term S100 refers to their
solubility in a 100%-saturated solution with ammonium
sulfate. To date at least 25 proteins have been identiﬁed as
belonging to the S100 protein family, characterized by the
presenceofapairofso-calledEF-hand(i.e.,helix-loop-helix)
calcium-binding motifs, ﬁrst discovered in the crystal struc-
ture of parvalbumin, that induce conformational changes
of the protein after binding to calcium. Most S100 proteins
exist as dimers (frequently homodimers) within cells and are
generally expressed and distributed in a cell-deﬁnite fashion,
indicating a conserved biological role. In this setting, S100B
is a homodimer of the beta subunit, mainly concentrated
in the nervous system and in the adipose tissue. In the
nervous system S100B appears to be most abundant in glial
cells and its presence in speciﬁc neuronal subpopulations has
also been described [2–6]. S100B is present intracellularly
and extracellularly; it is believed to regulate several cellular
functions (protein phosphorylation, protein degradation,
calcium homeostasis, cell locomotion, transcription factors,
cell proliferation and diﬀerentiation, enzymes, regulation
of receptor function, cytoskeleton) while its biological
intracellular role has not yet been completely elucidated
in unifying terms. An extracellular biological role is also
attributed to S100B, which is secreted by astrocytes as a
cytokine exerting an autocrine or paracrine eﬀect on glia,
neurons and microglia; the protein may have a trophic
eﬀect during both development and nerve regeneration at
physiologic (nanomolar) concentrations (the Jekyll side),
but at high (micromolar) concentrations (the Hyde side)
could be neurotoxic, participating in the pathophysiology
of neurodegenerative disorders [7–10]. In this respect, tran-
scriptional eﬀects of micromolar S100B on neuroblastoma
cells have been shown to result in perturbation of cholesterol
homeostasis and interference in the cell cycle [11]. Both
eﬀects of S100B on target cells are believed to be mediated
throughRAGEengagement[5].Apartfromitsstillunknown
function, the presence of S100B in biological ﬂuids is2 Cardiovascular Psychiatry and Neurology
interesting,sinceatpresentitconstitutesanestablishedindex
of brain injury [10]. It should be noted in this respect that its
half-life is approximately 1 hour and it is mainly eliminated
by the kidney [12]. In particular, the assessment of S100B
in biological ﬂuids has been usefully employed in perinatal
medicine [12, 13]. After its established use in conventional
ﬂuids (CSF, blood, urine, amniotic ﬂuid), this minireview is
focused on the assessment of S100B levels in unconventional
ﬂuids (saliva, milk), which may open new perspectives for
studies on this protein.
1.1. S100B and Conventional Biological Fluids. S100B protein
has been measured in several biological ﬂuids (cerebrospinal
ﬂuid, blood, urine and amniotic ﬂuid) by a series of
immunoassays, which have been variously used in diﬀerent
ﬂuids.
Cerebrospinal ﬂuid (CSF)was the ﬁrst of various bio-
logical ﬂuids in which the role of S100B as a marker of
active brain damage was demonstrated [14, 15]. In perinatal
medicine, measurements of S100B protein in CSF have
been used to monitor infants aﬀected by perinatal asphyxia
and post-hemorrhagic ventricular dilatation brain damage
duringcardiacsurgery.S100Bconcentrationscorrelatedwith





S100B released from the damaged tissue could spread into
thesystemiccirculation[19],alsoasaresultofhemodynamic
rearrangement of the blood brain barrier. Increased blood
concentrations of S100B were indeed detected in cases of
chronic hypoxia and/or intraventricular hemorrhage (IVH)
in preterm infants, in full-term infants suﬀering by perinatal
asphyxia and adverse neurological outcomes [20–23]. S100B
wasalsomeasuredinthebloodofwomenwhosepregnancies
are complicated by intrauterine growth retard and whose
newborns develop intraventricular haemorrhage [24].
In the urine S100B concentrations at birth were signiﬁ-
cantly higher in preterm newborns developing intraventric-
ular haemorrhage and/or brain damage. In a cross-sectional
study using urine obtained from preterm newborns, the
protein has been found to be a valuable predictor of early
neonatal death [25–28].
In the amniotic ﬂuid S100B concentration has been
shown to correlate with gestational age and with cerebral
ultrasound scanning results in healthy fetuses [29]. In addi-
tion, amniotic S100B concentrations are higher in monoam-
niotic than in diamniotic and singleton pregnancies, hinting
at the possibility that each foetus releases a physiologically
deﬁned amount of S100B during pregnancy [30]. Elevated
S100B concentrations in the amniotic ﬂuid have also been
shown to constitute a reliable marker of foetus pathological
conditions, including trisomy 21 [31–35].
1.2. S100B and Unconventional Biological Fluids. Among
human biological ﬂuids, in the perinatal period, the studies
aimed at investigating the presence of S100B protein in
biological ﬂuids, namely “unconventional” biological ﬂuids
suchassalivaandmilk,areespeciallyintriguing.Inparticular
saliva,whichismoreeasilycollectedthanCSF,bloodorurine
oﬀers the hope of simple non-invasive tests especially useful
in perinatal medicine. This possibility could even represent
the reaching of the so called“gold standard” for non-invasive
longitudinal monitoring of occurring brain damage eagerly
awaited in clinical practice. Future prospects also include
the possibility of monitoring the true eﬀectiveness of the
even more risky therapeutic strategies such as mechanical
ventilation, brain cooling and experimental medications.
Even more interesting prospects are oﬀered by the detection
of S100B in breast milk, candidating the protein as a
participant in the biochemical communication between
mother and child. This might contribute to the identiﬁ-
cation of biochemical markers with a series of unknown
functions that to date conﬁrm that the role of maternal milk
instead of artiﬁcial ones in brain maturation involvement is
unique.
1.2.1. S100B and Saliva. The possibility that S100B could be
assessed in diﬀerent biological ﬂuids has been substantiated
in the last decade, thanks to continuous interactions among
physicians of several disciplines. In this regard, the concept
of minimal handling of patients derives from neonatologists
and perinatologists who need, in the phase of critical
intensive care medicine, non-invasive parameters able to
detect cases at risk of brain damage at the earliest stage in
order to prevent it. Among non-invasive biological ﬂuids
saliva meets the optimality requirements since it can be
collected any time without newborn stress, its measurements
are reproducible and can be compared with other “invasive”
biological ﬂuids.
Studies of human fetuses have shown that members
of the S100 protein family are present in diﬀerent tissues
of the salivary glands during ontogenesis. Results showed
that diﬀerent S100 proteins are expressed during diﬀerent
phases of pregnancy up to adulthood, whilst S100B in
particular has been found to be essentially absent from
fetal salivary glands from 32 weeks of gestation onwards
[36, 37]. Data on physiology of salivary glands reported
that systemic blood and saliva are isotonic and contain the
same concentrations of ions in the same ratios, thanks to a
continuous exchange of ions and protein between blood and
saliva. In addition, an increase or a decrease in the volume of
salivareleaseissystemiccirculation-dependentandmediated
by ortho/parasympathetic activation [38]. These ﬁndings
indicate that the salivary glands do not produce S100B in the
third trimester of pregnancy and that S100B concentrations
detected in saliva likely derive from systemic circulation.
The ﬁrst observation of the presence of S100B in saliva
was supported by immunoluminometric assay conﬁrmed
by Western blot analysis and also oﬀered a reference curve
of the protein in this biological ﬂuid in normal preterm
and term newborns [39]. Results showed that saliva can be
used in the clinical monitoring of S100B levels, which, as
already established for other biological ﬂuids, such as CSF,
blood, urine or amniotic ﬂuid, can constitute a reliable index
to diagnose/monitor brain distress. Since saliva samples
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performed on this biological ﬂuid appear to be especially
convenient in the clinical evaluation of newborns.
1.2.2. S100B and Milk. The hypothesis of assessing the
protein in a so complex biological ﬂuid was based on the
following elements: (i) S100 proteins are highly conserved
in amino acid composition among vertebrate species, sug-
gesting a pivotal, although still unknown, biological role
for the protein [40]; (ii) S100-like proteins have also been
immunologically detected in spinach leaves suggesting a
potential role in human food-chain [41], adipose tissue also
constitutes a site of concentration for the protein [42]; (iii)
breast milk is known to contain growth factors and cytokines
[43–46]; (iv) milk is abundant in other calcium-binding
proteins (e.g., alpha-lactalbumin, calmodulin, osteocalcin)
[47–49]. Results showed S100B in human breast milk; in
addition, S100B milk content was estimated to be 80/100
times higher than those detected in CSF, blood, urine
[50]. Interestingly, signiﬁcant diﬀerences have been found
in S100B milk concentrations among diﬀerent mammalian
species such as human, cow, goat, donkey and sheeps.
The S100B concentration is higher in human milk, thus
raising possible speculations on a relationship between
the milk concentration of this neurotrophic factor and
species evolution [51]. Western blot analysis conﬁrmed that
the immunoreactivity observed using immunoluminometric
assay refers to S100B protein and RT-PCR analysis also
detected human S100B mRNA in the human milk [50]. This
latter ﬁnding likely refers to the presence in the milk of cell
types expressing S100B, including mammary epithelial cells
and lymphocytes, which reasonably may be supposed to be
the source of S100B in the milk. The presence of S100B
at very high concentration in human breast milk may be
related to its putative neurotrophic role, given that breast-
feeding is believed to exert a stimulatory eﬀect on brain
maturation [52]. More detailed information will be needed
to corroborate the possibility that S100B may participate
in the nutritional aspects of milk, including possible eﬀects
on intestinal development and/or trophism of the enteric
nervoussystem.Inthisrespectitshouldbenotedthathuman
breastmilkisknowntocontaindiﬀerentsubstancesthatmay
actively inﬂuence infant growth and development, including
hormones, growth factors and cytokines [53]. Interestingly,
S100B levels in human breast milk signiﬁcantly increase
during milk maturation, being very low in colostrum,
intermediate in transition milk (7 and 14 days) and high
in mature milk (30 days) [54]. Further studies investigated
the impact of industrial preparation procedures (skimmed
cow milk, protein sources supplementation, pasteurization
and spray-drying procedures) on S100B content. Results
showed that S100B has a suﬃcient thermo-stability to resist
pasteurization but not spry-drying, suggesting that new
feeding strategies in preterm and term infants are therefore
warranted in order to preserve S100B and other potential
brain constituents during industrial preparation [55]. It may
be relevant in this respect that, thanks to the considerable
technological improvement in dietetics preparations and
progresses in laboratory biochemistry, evidence is growing
that artiﬁcial milks could need to be enriched with recent
discovered constituents: S100B can be included among these
on account of its neurotrophic properties.
Finally, apart from the possible trophic role on the
newborn exerted by the maternal breast milk, the examina-
tion of S100B level in this unconventional biological ﬂuid
could oﬀer new prospects in the investigation of maternal
physiopathological conditions with a potential direct impact
on the newborn health.
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